For information on open opportunities, review our job posting or email HR@AspirePartnersUSA.com
Chesapeake Bank is a community bank located in Kilmarnock, Virginia, serving the Northern Neck and Middle Peninsula regions. Established in April 1900 as Lancaster National Bank, it was founded to support local watermen, oystermen, and fishermen. Over the years, the bank has expanded its services to include farmers and various local businesses, adapting to the needs of the community. The bank offers a variety of banking services, including personal banking options like checking and savings accounts, personal loans, and credit cards. For businesses, Chesapeake Bank provides loans, lines of credit, and cash management services. Additionally, it offers investment services through Chesapeake Wealth Management. Known for its community-focused approach, Chesapeake Bank emphasizes treating customers like neighbors and actively engages in local initiatives.
Club Car Wash is a family-owned express car wash company based in Missouri. Founded in 2006 as Tiger Express Wash, it rebranded to Club Car Wash in 2019. The company has rapidly expanded to become one of the largest car wash chains in the Central United States, with over 213 locations and plans for 56 more by 2025. The company specializes in fast and convenient vehicle cleaning services, including exterior washes with advanced technology and various interior cleaning options. They offer membership and subscription plans for regular customers, as well as additional detailing services at select locations. Club Car Wash has grown through both organic development and acquisitions, enhancing its service offerings and geographic reach across multiple states. Their marketing focuses on quality, speed, and customer experience, catering to a diverse customer base that includes daily commuters and fleet operators.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.